Nishtman Dizeyi
Overview
Explore the profile of Nishtman Dizeyi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
478
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guo J, Gu L, Johnson H, Gu D, Lu Z, Luo B, et al.
Prostate Cancer Prostatic Dis
. 2024 Feb;
28(1):94-102.
PMID: 38308042
Background: Prostate cancer patients with pelvic lymph node metastasis (PLNM) have poor prognosis. Based on EAU guidelines, patients with >5% risk of PLNM by nomograms often receive pelvic lymph node...
2.
Auge C, Dizeyi N, Ramnemark L, Lluel P, Grabe M
Scand J Urol
. 2022 Jun;
56(4):320-328.
PMID: 35766197
Objective: Inflammation of the urinary bladder may cause burdensome pain also called bladder pain syndrome (BPS). A limitation in understanding BPS pathophysiology is the lack of appropriate preclinical model. Previously...
3.
Guo J, Zhang X, Xia T, Johnson H, Feng X, Simoulis A, et al.
Front Med (Lausanne)
. 2021 Oct;
8:721554.
PMID: 34595190
To avoid over-treatment of low-risk prostate cancer patients, it is important to identify clinically significant and insignificant cancer for treatment decision-making. However, no accurate test is currently available. To address...
4.
Guo J, Johnson H, Zhang X, Feng X, Zhang H, Simoulis A, et al.
Clin Transl Med
. 2021 Mar;
11(3):e340.
PMID: 33784002
No abstract available.
5.
Johnson H, Guo J, Zhang X, Zhang H, Simoulis A, Wu A, et al.
BMC Med
. 2020 Dec;
18(1):376.
PMID: 33256740
Background: Heterogeneity of prostate cancer (PCa) contributes to inaccurate cancer screening and diagnosis, unnecessary biopsies, and overtreatment. We intended to develop non-invasive urine tests for accurate PCa diagnosis to avoid...
6.
Larsson P, Syed Khaja A, Semenas J, Wang T, Sarwar M, Dizeyi N, et al.
Int J Cancer
. 2019 Aug;
146(6):1686-1699.
PMID: 31381135
Currently, no effective targeted therapeutics exists for treatment of metastatic prostate cancer (PCa). Given that matrix metalloproteinases 9 (MMP9) and its associated vascular endothelial growth factor (VEGF) are critical for...
7.
Dizeyi N, Mattisson I, Ramnemark L, Grabe M, Abrahamsson P
Phytother Res
. 2019 Jul;
33(9):2457-2464.
PMID: 31342610
The pollen extract Cernitin® is widely used for treatment of benign prostatic hyperplasia (BPH) and non-bacterial chronin prostatitis. However, little is known about the underlying molecular mechanisms to explain the...
8.
Dizeyi N, Trzybulska D, Al-Jebari Y, Huhtaniemi I, Lundberg Giwercman Y
Urol Oncol
. 2019 Jan;
37(4):290.e1-290.e8.
PMID: 30611646
Introduction: Conversion of androgen-responsive prostate cancer (CaP) to castration-resistant CaP is associated with an acceleration of the disease that often requires treatment modalities other than androgen deprivation therapy only. Recently,...
9.
Tinzl M, Chen B, Chen S, Semenas J, Abrahamsson P, Dizeyi N
PLoS One
. 2018 Dec;
13(12):e0209544.
PMID: 30562402
[This corrects the article DOI: 10.1371/journal.pone.0079573.].
10.
Sarwar M, Semenas J, Miftakhova R, Simoulis A, Robinson B, Wingren A, et al.
Oncotarget
. 2016 Sep;
7(39):63065-63081.
PMID: 27588408
One mechanism of resistance of prostate cancer (PCa) to enzalutamide (MDV3100) treatment is the increased expression of AR variants lacking the ligand binding-domain, the best characterized of which is AR-V7....